Genmab and AbbVie blood cancer drug combo cuts risk of progression or death

Danish biotech firm Genmab and US drugmaker AbbVie announced that their combination treatment for newly diagnosed patients with a type of lymphoma reduced the risk of disease progression or death in a late-stage study. Shares of US-listed Genmab were affected.